Hikma Pharmaceuticals PLC (HIK)

30.800
0.000(0.00%)
  • Volume:
    0
  • Bid/Ask:
    0.000/0.000
  • Day's Range:
    30.800 - 30.800
  • Type:Equity
  • Market:Germany
  • ISIN:GB00B0LCW083
  • WKN:A0HG69

HIK Overview

Prev. Close
30.8
Day's Range
30.8-30.8
Revenue
1.94B
Open
30.8
52 wk Range
23.49-30.8
EPS
0.68
Volume
0
Market Cap
7.09B
Dividend (Yield)
0.43
(1.40%)
Average Volume (3m)
70
P/E Ratio
24.51
Beta
1.18
1-Year Change
30.67%
Shares Outstanding
231,432,099
Next Earnings Date
-
What is your sentiment on Hikma Pharmaceuticals PLC?
or
Market is currently closed. Voting is open during market hours.

Hikma Pharmaceuticals PLC News

Hikma Pharmaceuticals PLC Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuyBuy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy

Hikma Pharmaceuticals PLC Company Profile

Hikma Pharmaceuticals PLC Company Profile

Employees
8681

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment develops, manufactures, and sells generic injectable products primarily for use in hospitals. The Generics segment develops, manufactures, and sells oral and other non-injectable generic products for the retail market. The Branded segment develops, manufactures, markets, and sells branded generics and in-licensed products to retail and hospital markets. The company offers its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, anesthetic, sedative, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

Read More
  • Touch 27 today
    0
    • Next results will be super. Wait for it to hit £32 before end of this year
      0
      • Aim listed Dark Matter Ltd, has more potential
        1
        • This will go up & up
          1
          • Not as stated here (March 11)
            1
            • Hikma will announce their results for the year ended 31 December 2019 on 27 February 2020
              0
              • Any hint of progress on Advair will send this stock much higher still !
                0
                • Underpriced without the Advair approvals ' unfortunate about the 2019 target for Advair !!!
                  0
                  • Almost got me money back !!!
                    0
                    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.